Press Room

FOR RELEASE

Investor Contact
Matt Clawson
Allen & Caron, Inc.
(949) 474-4300

www.allencaron.com

Media Contact
Len Hall
Allen & Caron, Inc.
(949) 474-4300

www.allencaron.com

For Additional Information:
Craig T. Davenport, CEO, President & Chairman
Michael R. Rodriguez, CFO
Endocare, Inc.
(949) 450-5400
www.endocare.com

About Endocare

Endocare, Inc.—www.endocare.com—is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing devices for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver.

Statements contained in this release that are not historical facts are forward looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward looking statements include, but are not limited to, those discussed in “Risk Factors” in the Company’s Forms 10 K, Forms 10 Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to: uncertainty regarding the Company's liquidity and ability to reach and maintain profitability; risks relating to the fact that the Company’s largest customer accounts for a significant percentage of the Company’s sales and accounts receivable; the risk that the Company may be required to make state and local tax payments that exceed the Company's settlement estimates; uncertainty regarding the Company's re listing on a national stock exchange; uncertainty regarding the effects of effectuating the Company's proposed reverse stock split, in particular the possibility that the market may react negatively to the Company's effectuation of a reverse stock split; uncertainty regarding market acceptance of the Company's products; uncertainty of product development and the associated risks related to clinical trials; uncertainty relating to third party reimbursement; uncertainty regarding the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; the Company's limited sales, marketing and manufacturing experience; uncertainty regarding the ability to attract and retain key personnel; uncertainty regarding the ability to secure and protect intellectual property rights relating to the Company's technology; the rapid pace of technological change in the Company's industry; fluctuations in the Company's order levels; and the risk that the Company may be subject to civil and criminal liability in the future if it is found to have violated the terms of the Company’s recent settlements with the Securities and Exchange Commission and the Department of Justice. The actual results that the Company achieves may differ materially from any forward looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

# # # #

Return to top